Abbott Labs shares jump 12% as Q2 sales rise, profit outlook raised

Abbott Labs reported Q2 adjusted diluted EPS of $1.31 (GAAP EPS $0.53) and raised its full-year 2026 adjusted EPS guidance to $5.45-$5.60 from the prior $5.38-$5.58 range. The company reaffirmed comparable sales growth guidance of 6.5% to 7.5%, helped by its acquisition of Exact Sciences. Shares jumped about 12% on the results and improved outlook.